HPLC-UV method for simultaneous determination of irbesartan, candesartan, gliquidone and pioglitazone in formulations and in human serum  

作　　者：Agha Zeeshan Mirza 

机构地区：[1]Science and Technology Unit, Umm Al-Qura University, Makah 21955, KSA

出　　处：《Journal of Chinese Pharmaceutical Sciences》2018年第4期273-280,共8页中国药学（英文版）

摘　　要：In this study, we reported and validated a novel and sensitive reversed-phase liquid chromatographic method for the simultaneous determination of irbesartan, candesartan, gliquidone and pioglitazone. Separation was performed at 230 nm using a mobile phase consisting of methanol–water(90:10, v/v) with a flow rate of 1 mL/min. p H was adjusted to 3.5 with phosphoric acid. The concentration-response relationship was found linear over a concentration range of 5–25 μg/mL for all of the analytes tested. The limits of detection and quantification were 0.83 and 2.78 for irbesartan, 0.30 and 1.01 for candesartan, 1.11 and 3.93 for gliquidone, and 0.41 and 1.41 μg/mL for pioglitazone, respectively. Described method permitted the successful determination of these drugs in human serum. The developed method was simple, rapid, and it did not require extensive sample purification.In this study, we reported and validated a novel and sensitive reversed-phase liquid chromatographic method for thesimultaneous determination of irbesartan, candesartan, gliquidone and pioglitazone. Separation was performed at 230 nm using amobile phase consisting of methanol-water （90：10, v/v） with a flow rate of 1 mL/min, pH was adjusted to 3.5 with phosphoricacid. The concentration-response relationship was found linear over a concentration range of 5-25 μg/mL for all of the analytestested. The limits of detection and quantification were 0.83 and 2.78 for irbesartan, 0.30 and 1.01 for candesartan, 1.11 and 3.93for gliquidone, and 0.41 and 1.41 μg/mL for pioglitazone, respectively. Described method permitted the successful determinationof these drugs in human serum. The developed method was simple, rapid, and it did not require extensive sample purification.

关 键 词：CANDESARTAN GLIQUIDONE IRBESARTAN PIOGLITAZONE RP-HPLC Method development 

分 类 号：R917[医药卫生—药物分析学]